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Aims To investigate the prevalence of electromagnetic interference (EMI) between left ventricular assist devices
(LVADs) and implantable cardioverter-defibrillators (ICDs)/pacemakers (PMs).
...................................................................................................................................................................................................
Methods
and results
A retrospective single-centre study was conducted, including all patients undergoing HeartMate II (HMII) and
HeartMate 3 (HM3) LVAD implantation (n=106). Electromagnetic interference was determined by the inability to
interrogate the ICD/PM. Overall, 85 (mean age 59± 8, 79% male) patients had an ICD/PM at the time of LVAD im-
plantation; 46 patients with HMII and 40 patients with HM3. Among the 85 LVAD patients with an ICD’s/PM’s, 11
patients (13%) experienced EMI; 6 patients (15%) with an HMII and 5 patients (11%) with an HM3 (P=0.59).
Electromagnetic interference from the HMII LVADs was only present in patients with a St Jude/Abbott device; 6 of
the 23 St Jude/Abbott devices. However, in the HM3 patients, EMI was mainly present in patients with Biotronik
devices: 4 of the 18 with only one (1/25) patient with a Medtronic device. While initial interrogation of these devi-
ces was not successful, none of the 11 cases experienced pacing inhibition or inappropriate shocks.
...................................................................................................................................................................................................
Conclusion In summary, the prevalence of EMI between ICDs in the older and newer type of LVAD’s remains rather high.
While HMII patients experienced EMI with a St Jude/Abbott device (which was already known), HM3 LVAD
patients experience EMI mainly with Biotronik devices. Prospective follow-up, preferably in large registries, is war-
ranted to investigate the overall prevalence and impact of EMI in LVAD patients.
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Introduction
Left ventricular assist device (LVAD) therapy is increasingly utilized
to treat end-stage heart failure patients who are in dire need of circu-
latory support.1 Most patients who are eligible for continuous-flow
LVAD therapy, already have an implantable cardioverter-defibrillator
(ICD) and/or pacemaker (PM) implanted.1 However, following
LVAD implantation, electromagnetic interference (EMI) can occur
between the LVAD and the ICD/PM. Recently, multiple cases of EMI
between LVADs and ICD’s/PM’s have been reported.2–4 The EMI
hinders the interrogation of the ICD/PM’s and leaves clinicians in the
dark. Therefore, the aim of the present study was to investigate the
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prevalence of EMI between different types of ICD/PM in patients
implanted with HeartMate II (HMII) and the recently introduced
HeartMate 3 (HM3).
Methods
Study design
We reviewed all patients who received an LVAD between December
2006 and February 2019 in our tertiary referral centre with a prior ICD/
PM implantation or device replacement due to end-of-life. The study was
approved by the institutional review board of the Erasmus MC Medical
Centre Rotterdam.
Endpoints
The primary outcome was the occurrence of EMI, defined as ICD/PM te-
lemetry interference (i.e. the inability to interrogate ICD/PM).
Data collection
All data were obtained from the electronic patient records. Baseline char-
acteristics were collected pre-operatively for all patients. Devices in-
cluded were the HMII, HM3 (Abbott, IL, USA).
Statistical analysis
Continuous parameters are expressed as median and inter-quartile range
or mean and standard deviation, depending on the distribution.
Categorical parameters were expressed as number and percentage and
compared by v2 test. Analyses were performed using the SPSS statistical
software package, version 24.0 for Mac (SPSS Inc., IBM Company,
Chicago, IL, USA).
Results
In total, 109 patients received an LVAD (mean age at implantation
52± 12, 83% male). Overall, 86 (mean age 59± 8, 79% male) patients
had an ICD (n = 85) or PM (n = 1) at the time of LVAD implantation;
46 patients with HMII and 40 with HM3. One patient with an ICD
was excluded from further analysis because of missing follow-up data.
None of the ICDs/PMs showed any abnormalities prior to the LVAD
implantation. The implanted ICD/PM devices were from Medtronic
(Dublin, Ireland) (n=25), St Jude/Abbott (Chicago, IL, USA) (n=23),
Biotronik (Berlin, Germany) (n=18), Boston Scientific (Marlborough,
MA, USA) (n=18), and Microport (Shanghai, China) (n=1) (see
Figure 1). Among the 85 LVAD patients with an ICD’s/PM’s, 11
patients (13%) experienced EMI; 6 ICD patients (15%) with an HMII
and 5 ICD patients (11%) with an HM3 (P=0.59).
Electromagnetic interference from the HMII LVADs was only pre-
sent in patients with a St Jude/Abbott device; 6 of the 23 St Jude/
Abbott devices (1 Atlas, 1 Unify, 1 Fortify, 1 Elipse, and 2 Promote).
However, in the HM3 patients, EMI was mainly present in patients
with Biotronik devices: 4 of the 18 (device types: Lumax, Ilivia, Ilesto,
and Iperia) with only one (1/25) patient with a Medtronic (Claria) de-
vice (see Table 1 for complete overview). None of the PM patients
showed any signs of EMI.
Clinical outcomes
In 4 out of 11 patients, interrogation could not be performed in any
form. For the other seven patients, with some minor adjustments, in-
terrogation was made possible. While initial interrogation of these
devices was not successful, none of the 11 cases experienced pacing
inhibition or inappropriate shocks.
Discussion
The current study was aimed to gain insight on the prevalence of EMI
between the HMII and HM3 LVAD’s and several ICD/PM device
types. The principal findings are as follows: (i) EMI is present in 13%
of LVAD patients with ICD’s in situ. (ii) In patients with an HMII, EMI
is present only when they had an ICD from St Jude/Abbott implanted.
However, in HM3 LVAD patients, EMI was mainly present in patients
with ICD’s from Biotronik. (iii)While 11 patients presented with diffi-
culties regarding interrogation of their ICD, none of the patients ex-
perienced pacing inhibition or inappropriate shocks.
Currently, the LVAD literature mainly describes EMI in patients
with a St Jude/Abbott device. Yet in the more recent HM3 type
LVADs, it almost exclusively occurred in patients who had received a
Biotronik device. Recently, several reported cases noticed the occur-
rence EMI between a Biotronik ICD and an HM3 LVAD.2–4 This
emerging phenomenon warrants increased vigilance as an increasing
number of patients receive HM3 LVAD therapy. Of note, since in
our single cohort, no pacing inhibition or inappropriate shock has
been administered, the clinical implication of the phenomenon
appears limited. However, in larger cohorts with longer follow-up
and/or emergency settings, the recognition of this phenomenon, the
possible following complications and subsequent appropriate ap-
proach of EMI between ICD and LVAD could be of paramount
importance.
The occurrence of EMI most likely occurs due to the magnetic
components of the HMII and HM3 LVAD’s, which hinder the interro-
gation of the ICD. The use of radiofrequency (RF), which is not af-
fected by EMI, could be used to bypass this issue. Therefore,
activating the RF use prior to LVAD implantation (if possible) should
be considered. In patient with an LVAD in situ this is no longer is an
option. Nonetheless, RF use can be beneficial. However, to activate
the RF use, initial contact with the ICD is required. To achieve this, it
seems that the distance between the ICD and the LVAD must be in-
creased. Raising the ipsilateral arm and/or raising the ICD in its pocket
can create enough distance to enable RF use. Alternatively, a Faraday
cage (using copper or iron plates) can be put over the area with the
LVAD to minimize EMI and enable RF use. Unfortunately, in some
What’s new?
• Left ventricular assist device (LVAD) therapy is increasingly
utilized to treat end-stage heart failure patients. However,
following LVAD implantation, electromagnetic interference
(EMI) can occur, in this study mainly between HeartMate 3
and Biotronik ICD devices.
• Following a stepwise approach could enable interrogation of
the ICD/PM; however, in some cases surgical repositioning is
necessary.
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Table 1 Electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist
devices observed in study population
Patient ICD
manufacturer
Type LVAD
type
Indication Support
duration
Type of EMI Intervention
1 St Jude Medical Unify (CRT-D) HMII Bridge-to-transplantation 25 days Interference with telemetry
function
RF use
2 St Jude Medical Elipse (ICD) HMII Bridge-to-transplantation 203 days Interference with telemetry
function
No interrogation
possible
3 St Jude Medical Atlas (ICD) HMII Bridge-to-transplantation 287 days Interference with telemetry
function
No interrogation
possible
4 St Jude Medical Fortify (ICD) HMII Bridge-to-transplantation 970 days Dysfunction ICD systema Device replacement
5 St Jude Medical Promote (CRT-D) HMII Bridge-to-transplantation 1061 days Interference with telemetry
function
RF use
6 St Jude Medical Promote (CRT-D) HMII Bridge-to-transplantation 1886 days Interference with telemetry
function
RF use
7 Biotronik Ilesto (CRT-D) HM3 Bridge-to-decision 199 days Interference with telemetry
function
Patient in lying
position
8 Medtronic Viva (CRT-D) HM3 Bridge-to-transplantation 275 days Interference with telemetry
function
No interrogation
possible
9 Biotronik Iperia (CRT-D) HM3 Destination therapy 348 days Interference with telemetry
function
Uplift device
10 Biotronik Ilivia (CRT-D) HM3 Bridge-to-transplantation 724 days Interference with telemetry
function
No interrogation
possible
11 Biotronik Lumax (ICD) HM3 Bridge-to-transplantation 997 days Interference with telemetry
function
Patient in lying
position
CRT-D, cardiac resynchronization therapy defibrillator; EMI, electromagnetic interference; HM, HeartMate; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular
assist device; RF, radiofrequency.
aAfter implantation of the LVAD, the ICD device appeared to be in back-up mode (VVI 65 bpm) and shock therapy was disabled. After a multidisciplinary consultation (together
with Abbott), it was decided to replace the ICD device. The cause of this problem was attributed to the EMI generated by the implanted HMII. Following the replacement with
a device from a different manufacturer, no further issues were observed.
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Figure 1 Cardiac implantable electronic device manufacturer distribution among the HeartMate II and HeartMate 3 left ventricular assist device
types. HM, HeartMate.
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cases, these methods were insufficient, and the ICD could not be in-
terrogated. These situations could benefit from surgical intervention
to increase the distance between both devices. This could be done
by implanting the ICD in the contra-lateral side (see Figure 2 for com-
plete overview). While no pacing inhibition took place or inappropri-
ate shocks were administered, the EMI between the LVAD and the
ICD hampers optimal ICD therapy. As this is a retrospective study,
to further elucidate the effect of EMI between the contemporary
HM3 LVAD and ICDs, prospective registries like the interagency reg-
istry for mechanically assisted circulatory support (INTERMACS) and
the European registry for patients with mechanical circulatory sup-
port (EUROMACS) should incorporate these findings.
Conclusion
In summary, the prevalence of EMI between ICDs in the older and
newer type of LVAD’s remains rather high. While HM2 patients ex-
perienced EMI with a St Jude/Abbott device (which was already
known), in our single-centre cohort, the HM3 LVAD patients experi-
ence EMI mainly with Biotronik devices. Ensuring enough distance
between the ICD and the LVAD seems to be beneficial. The pro-
vided methods can aid clinicians who experience similar problems
with the interrogation of the ICD of their LVAD patients. While the
aforementioned options to bypass this issue exist, they are some-
times inadequate. We, therefore, recommend further research, pref-
erably conducted via prospective multicentre registries, to elucidate
the full extent of the currently observed issue.
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1- Acvate radio 
frequency use 
prior to implantaon!
2 - Raise the arm 
ipsilateral to the ICD* 
3 - Raise the ICD in its 
pocket to increase the 
distance to the LVAD* 
4 - Place a copper or iron 
plate on the chest, in 
close proximity to the 
LVAD and repeat
previous 2 steps*
5 - Surgical 
intervenon by
relocang the ICD to 
the contra-laterale
side*
*Enable radio frequency use
as soon as possible if inial
contact is established to 
prevent further EMI issue   
Pre-operave
Post-operave
Figure 2 A stepwise approach to reduce the occurrence and impact of electromagnetic interference in left ventricular assist device patients.
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